552 related articles for article (PubMed ID: 29669399)
1. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.
Unlu O; Erkan D; Barbhaiya M; Andrade D; Nascimento I; Rosa R; Banzato A; Pengo V; Ugarte A; Gerosa M; Ji L; Efthymiou M; Branch DW; de Jesus GR; Tincani A; Belmont HM; Fortin PR; Petri M; Rodriguez E; Pons-Estel GJ; Knight JS; Atsumi T; Willis R; Zuily S; Tektonidou MG;
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):134-141. PubMed ID: 29669399
[TBL] [Abstract][Full Text] [Related]
2. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.
Frodlund M; Vikerfors A; Grosso G; Skogh T; Wetterö J; Elvin K; Gunnarsson I; Kastbom A; Dahlström Ö; Rönnelid J; Svenungsson E; Sjöwall C
Clin Exp Immunol; 2018 Oct; 194(1):27-38. PubMed ID: 30208508
[TBL] [Abstract][Full Text] [Related]
4. Altered β
Mobarrez F; Gunnarsson I; Svenungsson E
J Thromb Haemost; 2017 Sep; 15(9):1799-1806. PubMed ID: 28667788
[TBL] [Abstract][Full Text] [Related]
5. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
6. High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients.
Elbagir S; Elshafie AI; Elagib EM; Mohammed NA; Aledrissy MI; Manivel VA; Pertsinidou E; Nur MA; Gunnarsson I; Svenungsson E; Rönnelid J
Lupus; 2020 Oct; 29(11):1412-1422. PubMed ID: 32741301
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
[TBL] [Abstract][Full Text] [Related]
8. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.
Danowski A; Kickler TS; Petri M
J Rheumatol; 2006 Sep; 33(9):1775-9. PubMed ID: 16960938
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes.
Yelnik CM; Porter TF; Branch DW; Laskin CA; Merrill JT; Guerra MM; Lockshin MD; Buyon JP; Petri M; Sammaritano LR; Stephenson MD; Kim MY; Salmon JE
Arthritis Rheumatol; 2016 Aug; 68(8):1964-9. PubMed ID: 26990620
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus.
Tebo AE; Willis R; Jaskowski TD; Guerra M; Pierangeli SS; Salmon J; Petri M; Branch DW
Clin Chim Acta; 2016 Sep; 460():107-13. PubMed ID: 27346478
[TBL] [Abstract][Full Text] [Related]
11. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
[TBL] [Abstract][Full Text] [Related]
12. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
Front Immunol; 2019; 10():885. PubMed ID: 31134052
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
Martínez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Rueda M; Aguirre C
Lupus; 2004; 13(12):927-33. PubMed ID: 15645748
[TBL] [Abstract][Full Text] [Related]
14. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.
Ramos-Casals M; Campoamor MT; Chamorro A; Salvador G; Segura S; Botero JC; Yagüe J; Cervera R; Ingelmo M; Font J
Lupus; 2004; 13(10):777-83. PubMed ID: 15540510
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
Riancho-Zarrabeitia L; Martínez-Taboada V; Rúa-Figueroa I; Alonso F; Galindo-Izquierdo M; Ovalles J; Olivé-Marqués A; Fernández-Nebro A; Calvo-Alén J; Menor-Almagro R; Tomero-Muriel E; Uriarte-Isacelaya E; Botenau A; Andres M; Freire-González M; Santos Soler G; Ruiz-Lucea E; Ibáñez-Barceló M; Castellví I; Galisteo C; Quevedo Vila V; Raya E; Narváez-García J; Expósito L; Hernández-Beriaín JA; Horcada L; Aurrecoechea E; Pego-Reigosa JM
Lupus; 2020 Oct; 29(12):1556-1565. PubMed ID: 32807021
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies.
Harel L; Sandborg C; Lee T; von Scheven E
J Rheumatol; 2006 Sep; 33(9):1873-7. PubMed ID: 16845706
[TBL] [Abstract][Full Text] [Related]
18. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis.
Abdel-Wahab N; Talathi S; Lopez-Olivo MA; Suarez-Almazor ME
Lupus; 2018 Apr; 27(4):572-583. PubMed ID: 28945149
[TBL] [Abstract][Full Text] [Related]
19. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients.
Kozora E; Erkan D; Zhang L; Zimmerman R; Ramon G; Ulug AM; Lockshin MD
Clin Exp Rheumatol; 2014; 32(1):34-40. PubMed ID: 24021640
[TBL] [Abstract][Full Text] [Related]
20. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
Fischer K; Brzosko M; Walecka A; Ostanek L; Sawicki M
Pol Arch Med Wewn; 2007; 117 Suppl():13-7. PubMed ID: 18778013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
